Free Trial

Atea Pharmaceuticals (AVIR) Stock Forecast & Price Target

-0.11 (-2.99%)
(As of 07/19/2024 ET)

Atea Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 1 Wall Street analysts who have issued ratings for Atea Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Strong Sell." Out of the 1 analysts, 1 has given a sell rating for AVIR.

Consensus Price Target


According to the 1 analysts' twelve-month price targets for Atea Pharmaceuticals,

TypeCurrent Forecast
7/20/23 to 7/19/24
1 Month Ago
6/20/23 to 6/19/24
3 Months Ago
4/21/23 to 4/20/24
1 Year Ago
7/20/22 to 7/20/23
Consensus Rating
Strong Sell
Strong Sell
Strong Sell
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetN/AN/AN/A$6.00
Forecasted UpsideN/AN/AN/A38.46% Upside
Get Atea Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter.

AVIR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AVIR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Atea Pharmaceuticals Stock vs. The Competition

TypeAtea PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
Consensus RatingStrong SellModerate BuyModerate Buy
Predicted Upside3,376.49% Upside10.13% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/10/2023JPMorgan Chase & Co.
3 of 5 stars
 DowngradeNeutral ➝ Underweight
1/27/2023SVB Leerink
1 of 5 stars
 Lower TargetMarket Perform$8.00 ➝ $6.00+31.29%
1/24/2023Morgan Stanley
3 of 5 stars
 Lower TargetUnderweight$7.00 ➝ $4.00-15.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:54 PM ET.

AVIR Forecast - Frequently Asked Questions

Should I buy or sell Atea Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last year. There is currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" AVIR shares.

Do Wall Street analysts like Atea Pharmaceuticals more than its competitors?

Analysts like Atea Pharmaceuticals less than other "medical" companies. The consensus rating for Atea Pharmaceuticals is Strong Sell while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AVIR compares to other companies.

This page (NASDAQ:AVIR) was last updated on 7/19/2024 by Staff

From Our Partners